Search results for "Epidemiology."

showing 10 items of 4198 documents

Catechol-O-Methyltransferase Gene Polymorphism Is Associated with Skeletal Muscle Properties in Older Women Alone and Together with Physical Activity

2008

BackgroundMuscle strength declines on average by one percent annually from midlife on. In postmenopausal women this decrement coincides with a rapid decline in estrogen production. The genetics underlying the effects of estrogen on skeletal muscle remains unclear. In the present study, we examined whether polymorphisms within COMT and ESR1 are associated with muscle properties and assessed their interaction and their combined effects with physical activity.Methodology/principal findingsA cross-sectional data analysis was conducted with 434 63-76-year-old women from the population-based Finnish Twin Study on Aging. Body anthropometry, muscle cross-sectional area (mCSA), isometric hand grip a…

medicine.medical_specialtymedicine.drug_classScienceeducationPhysical activityWomen's Health/Menopause and Post-Reproductive Women's HealthCatechol O-Methyltransferase03 medical and health sciences0302 clinical medicinePolymorphism (computer science)Internal medicineHand strengthGenetics and Genomics/Population GeneticsMedicineHumansMuscle SkeletalExercise030304 developmental biologyAged0303 health sciencesMultidisciplinaryCatechol-O-methyl transferasePolymorphism Geneticbusiness.industryPhysiology/EndocrinologyQRSkeletal muscleESR1 and Skeletal MuscleMiddle Aged314 Health sciencesTwin studyCOMTEndocrinologymedicine.anatomical_structureEstrogenMedicineESR1 ja luurankolihasFemalePublic Health and Epidemiology/EpidemiologybusinessEstrogen receptor alpha030217 neurology & neurosurgeryResearch ArticlePLoS ONE
researchProduct

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

2020

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who hav…

medicine.medical_specialtymedicine.drug_classantithrombotic therapyCoronavirus disease 2019; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosisDisease030204 cardiovascular system & hematologyantiplateletPathogenesis03 medical and health sciences0302 clinical medicineAntithromboticEpidemiologyMedicine030212 general & internal medicinePlatelet activationEndothelial dysfunctionIntensive care medicinethrombosisCoronavirus disease 2019SARS-CoV-2business.industryanticoagulantAnticoagulantmedicine.diseaseThrombosisCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct

Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant …

2020

GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular).

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment1700Antibioticslcsh:MedicinemicrobiomeGraft vs Host DiseaseHematopoietic stem cell transplantationantibioticsAntimicrobial StewardshipFecesInternal medicinegraft versus host diseasemicrobiotamedicineHumansMulticenter Studies as Topic1506infectionsLongitudinal StudiesProspective StudiesAntibiotic prophylaxisbusiness.industryIncidence (epidemiology)lcsh:RHematopoietic Stem Cell TransplantationGeneral MedicineAntibiotic Prophylaxismedicine.diseaseTransplant RecipientsGastrointestinal MicrobiomeTransplantationObservational Studies as Topicsurgical procedures operativeGraft-versus-host diseaseResearch DesignCase-Control StudiesCohortObservational studybusinessHaematology (Incl Blood Transfusion)BMJ Open
researchProduct

Women, thrombosis, and cancer: A gender-specific analysis.

2017

Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPregnancy Complications CardiovascularLow molecular weight heparin030204 cardiovascular system & hematologyPregnancy Complications Cardiovascular/drug therapy/epidemiology03 medical and health sciences0302 clinical medicinePregnancyRisk FactorsInternal medicineNeoplasmsAntithromboticMedicineHumanscardiovascular diseasesddc:616Venous Thromboembolism/drug therapy/epidemiologybusiness.industryAromatase InhibitorsAnticoagulantCancerAnticoagulantsThrombosisHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesThrombosisNeoplasms/complications/epidemiologySurgeryPostmenopauseVenous thrombosisAnticoagulants/therapeutic use030220 oncology & carcinogenesisFemaleHormone therapybusinessComplicationPregnancy Complications NeoplasticPregnancy Complications Neoplastic/epidemiologyThrombosis/drug therapy/epidemiologyAromatase Inhibitors/therapeutic useThrombosis research
researchProduct

Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature.

2018

Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give indications on anticoagulation in patients with thrombocytopenia. In …

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentvenous thromboembolismLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyVte prophylaxis03 medical and health sciences0302 clinical medicineAntithromboticmedicineAnimalsHumanscardiovascular diseasesIntensive care medicineChemotherapybusiness.industryIncidence (epidemiology)IncidenceCancerAnticoagulantsHematologyVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseaseThrombocytopeniaSevere thrombocytopeniaOncology030220 oncology & carcinogenesisHematologic NeoplasmsbusinessVenous thromboembolismCritical reviews in oncology/hematology
researchProduct

Frequency and determinants for hemorrhagic transformation of posterior cerebral stroke : Posterior ischemic stroke and hemorrhagic transformation.

2017

BACKGROUND: hemorrhagic transformation is a threatening ischemic stroke complication. Frequency of hemorrhagic transformation differs greatly among studies, and its risk factors have been usually studied in patients with anterior ischemic stroke who received thrombolytic therapy. We evaluated, in a hospital-based series of patients with posterior ischemic stroke not treated with thrombolysis, frequency and risk factors of hemorrhagic transformation. Patients with posterior circulation stroke were seen in our Department during the period January 2004 to December 2009. Demographic and clinical information were collected. We estimated risk for spontaneous hemorrhagic transformation by means of…

medicine.medical_specialtymedicine.medical_treatmentCerebral strokeLogistic regressionGeneral Biochemistry Genetics and Molecular BiologyBrain ischemia03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicinebiochemistry030212 general & internal medicineStrokebusiness.industryposterior ischemic strokegenetics and molecular biology (all)epidemiology; hemorrhagic transformation; posterior ischemic stroke; biochemistry genetics and molecular biology (all)General MedicineThrombolysismedicine.diseaseSurgeryhemorrhagic transformationIschemic strokeCardiologyepidemiologyComplicationbusiness030217 neurology & neurosurgery
researchProduct

Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment.

2015

Background and Aims: Amyloidosis is a rare complication of inflammatory bowel disease [IBD]; its low prevalence has hindered both descriptive and therapeutic studies. The aim of this study was to estimate the prevalence of amyloidosis in IBD and the risk factors associated with this complication. Methods: This paper presents an observational study, followed by a systematic review of the epidemiological and clinical characteristics of the disease and a review of the diagnostic and therapeutic options. Results: The prevalence of amyloidosis among IBD patients is 0.53% (95% confidence interval [CI]: 0.32–0.75), although epidemiological data suggest that it may be under-diagnosed. The phenotype…

medicine.medical_specialtymedicine.medical_treatmentDiseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologymedicinePrevalenceHumansProteinuriabusiness.industryAmyloidosisGastroenterologyImmunosuppressionGeneral MedicineAmyloidosismedicine.diseaseInflammatory Bowel DiseasesSurgeryPhenotypeTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyObservational studymedicine.symptomComplicationbusinessJournal of Crohn'scolitis
researchProduct

Tobacco smoking and risk of endometriosis: a systematic review and meta-analysis

2014

Objective Since conflicting results have been published on the role of tobacco smoking on the risk of endometriosis, we provide an up-to-date summary quantification of this potential association. Design We performed a PubMed/MEDLINE search of the relevant publications up to September 2014, considering studies on humans published in English. We searched the reference list of the identified papers to find other relevant publications. Case–control as well as cohort studies have been included reporting risk estimates on the association between tobacco smoking and endometriosis. 38 of the 1758 screened papers met the inclusion criteria. The selected studies included a total of 13 129 women diagn…

medicine.medical_specialtymedicine.medical_treatmentEndometriosisMEDLINEEndometriosisGlobal HealthRisk FactorsInternal medicineEpidemiologyObstetrics and Gynaecologymedicine1845EPIDEMIOLOGYHumans1506Gynecologybusiness.industry1731Risk FactorResearchSmokingGeneral MedicineGYNAECOLOGYFormer Smokermedicine.diseaseSettore MED/40 - Ginecologia E Ostetricia1692Relative riskMeta-analysisSmoking cessation1734FemaleSmoking CessationMorbiditybusinessCohort studyHumanBMJ Open
researchProduct

Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

2018

Objective: To characterize the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically guided multivariable model. Patients and Methods: The Spanish Group of Autoimmune Diseases HLH Study Group, formed in 2013, is aimed at collecting adult patients with HLH diagnosed in internal medicine departments between January 3, 2013, and October 28, 2017. Results: The cohort consisted of 151 patients (91 men; mean age, 51.4 years). After a mean follow-up of 17 months (range, 1-142 months), 80 patients died. Time-to-event analyses for death identified a worse survival curve f…

medicine.medical_specialtymedicine.medical_treatmentHLH hemophagocytic lymphohistiocytosislaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGC glucocorticoidEpidemiologymedicine030212 general & internal medicineSurvival analysislcsh:R5-920Hemophagocytic lymphohistiocytosisID immunosuppressive drugbusiness.industryMortality ratemedicine.diseaseICU intensive care unitIntensive care unitIVIG intravenous immunoglobulinImmunosuppressive drug030220 oncology & carcinogenesisCohortEtiologylcsh:Medicine (General)businessNK natural killerMayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct